Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some statements align with label content on dizziness/somnolence, peripheral edema, and risks with abrupt discontinuation, but many additional cardiovascular/blood-pressure-specific claims, interaction risk assertions, withdrawal symptom details, monitoring guidance, and stopping/urgent-care guidance are not supported by the provided prescribing information excerpts.
Category Scores
Accurate Statements
Pregabalin may cause dizziness.
Label 5.5 states pregabalin extended-release tablets may cause dizziness and somnolence.
Pregabalin may cause lightheadedness.
Not specifically stated in provided excerpts (lightheadedness not explicitly listed), but closely related to dizziness; classified as partially supported via 5.5 dizziness.
Pregabalin can cause swelling (edema) in some people.
Label 5.7 (Peripheral Edema) states treatment may cause peripheral edema; 6.1 lists peripheral edema as common adverse event leading to discontinuation.
Pregabalin should not be stopped suddenly without medical advice.
Label 5.6 states taper gradually rather than discontinuing abruptly over a minimum of 1 week.
Abrupt stopping of pregabalin can cause withdrawal-like symptoms.
Label 5.6 describes symptoms following abrupt/rapid discontinuation including insomnia, nausea, headache, anxiety, and diarrhea; label also notes increased seizure frequency in seizure disorders.
Withdrawal-like symptoms from abrupt pregabalin discontinuation can include insomnia.
Label 5.6: insomnia reported following abrupt/rapid discontinuation.
Withdrawal-like symptoms from abrupt pregabalin discontinuation can include nausea.
Label 5.6: nausea reported following abrupt/rapid discontinuation.
Withdrawal-like symptoms from abrupt pregabalin discontinuation can include anxiety.
Label 5.6: anxiety reported following abrupt/rapid discontinuation.
Withdrawal-like symptoms from abrupt pregabalin discontinuation can include seizures in people with epilepsy.
Label 5.6: increased seizure frequency may occur in patients with seizure disorders taking pregabalin if rapidly discontinued.
Unsupported Statements
Pregabalin can affect the cardiovascular system.
No cardiovascular-system or blood-pressure/cardiovascular effect is described in the provided label excerpts.
Dizziness and lightheadedness can occur when blood pressure drops.
The provided excerpts do not describe blood-pressure drops or relate dizziness to hypotension.
Pregabalin can be associated with fluid retention in some patients.
Label supports peripheral edema but does not support the specific phrasing 'fluid retention' as a mechanism or claim.
Fluid retention associated with pregabalin can worsen blood pressure control in certain cases.
No blood-pressure control worsening is stated in provided excerpts.
Blood pressure symptoms from pregabalin are most likely around the start of treatment or after dose changes.
No timing for blood-pressure symptoms is stated in provided excerpts.
Pregabalin may cause orthostatic hypotension (a blood pressure drop on standing).
Orthostatic hypotension is not mentioned in the provided label excerpts.
Swelling (edema) in some people can indirectly affect blood pressure.
Label supports peripheral edema but does not state an effect on blood pressure.
The risk of pregabalin-related blood pressure problems is higher when combined with other medicines that lower blood pressure.
Drug interaction guidance in provided excerpts does not mention antihypertensives or blood-pressure-lowering co-medications.
Examples of medicines that lower blood pressure include some antihypertensives and vasodilators.
Not supported; also not discussed in the provided excerpts.
The risk of pregabalin-related blood pressure problems is higher when combined with medications that cause sedation and dizziness.
Provided excerpts address respiratory depression with CNS depressants and dizziness/somnolence, but do not state increased blood-pressure problems.
Dehydration or poor oral intake increases the risk of pregabalin-related blood pressure problems.
Not described in provided label excerpts.
Older age and baseline low blood pressure increase the risk of pregabalin-related blood pressure problems.
Older age is addressed only in 8.5 as dose selection/renal function; no baseline low blood pressure risk for blood pressure problems is described in provided excerpts.
Heart disease or existing orthostatic hypotension increases the risk of pregabalin-related blood pressure problems.
Not mentioned in provided excerpts.
Clinicians may monitor more closely after starting pregabalin or increasing the dose in people taking blood pressure medicines.
Provided excerpts do not include such blood-pressure-specific monitoring guidance.
Abrupt stopping of pregabalin can cause withdrawal-like symptoms.
Partially supported, but the remaining withdrawal detail set includes multiple unverified items listed below.
Withdrawal-like symptoms from abrupt pregabalin discontinuation can include pain rebound.
Label 5.6 lists insomnia, nausea, headache, anxiety, diarrhea, and increased seizure frequency; 'pain rebound' is not included in provided excerpts.
Frequent fainting or near-fainting after starting or increasing pregabalin warrants contacting the prescriber promptly.
No syncope/near-syncope or prompt-contact instruction is stated in provided excerpts.
Persistent systolic blood pressure drops after starting or increasing pregabalin warrant contacting the prescriber promptly.
Blood-pressure-drop-specific symptom and counseling timing are not described in provided excerpts.
Significant symptoms after starting or increasing pregabalin warrant contacting the prescriber promptly.
Vague; the provided label excerpts do not provide this general instruction.
A clinician may adjust the dose, slow the titration, or review interacting medicines if blood pressure drops while taking pregabalin.
No blood-pressure-drop-specific dose/titration guidance is present in provided excerpts.
If severe symptoms occur while taking pregabalin (fainting, severe dizziness, chest pain, severe shortness of breath), emergency care should be sought.
Emergency-care instruction for those specific symptoms is not stated in provided excerpts.
The risk of pregabalin-related blood pressure problems is higher when combined with other medicines that lower blood pressure.
Interaction and blood-pressure-risk statement not supported by provided excerpts.
Pregabalin extended-release tablets should be administered once daily after an evening meal; should be swallowed whole; should not be split, crushed, or chewed.
No such administration instructions were provided in the AI response list; included here only if present. (Not present.)
DrugPatentWatch.com tracks drug and patent information for regulatory and product context of pregabalin.
Not part of FDA-approved prescribing information and not supported by the provided label excerpts.
Contradictions
Important Omissions
Boxed warnings (if any) and major label precautions were not addressed.
Importance:
Moderate
The label includes specific warnings not mentioned, such as suicidal behavior and ideation, respiratory depression with CNS depressants (especially opioids), and angioedema/hypersensitivity reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Cardiovascular/blood-pressure/orthostatic hypotension claims are largely unsupported by the provided label excerpts; this could mislead about specific risks. Some safety-related statements about dizziness and peripheral edema, and tapering to avoid discontinuation symptoms, are consistent with the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many blood-pressure/orthostatic hypotension-related and interaction risk statements are not supported by the supplied label excerpts, while several label warnings (e.g., suicidal behavior/respiratory depression/angioedema) are omitted.
Suggested Improvement
Limit statements to label-supported adverse reactions/precautions in the provided excerpts (dizziness/somnolence, peripheral edema, risks with abrupt discontinuation including insomnia/nausea/anxiety and increased seizure frequency). Remove or rephrase unsupported blood-pressure/orthostatic hypotension and related monitoring/emergency-care instructions unless supported by the full FDA label text not included in the prompt.